Palliative pancreatectomy with postoperative gemcitabine for patients with advanced pancreatic cancer

Journal of Gastroenterology

Volumn 43, Issue 3, 2008, Pages 233-238

  Fujino, Yasuhiro ^a,b   Sakai, Tetsuya ^a   Kuroda, Yoshikazu ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO CANCER CENTER   (Japan)

Author keywords

Gemcitabine; Palliative pancreatectomy; Pancreatic cancer

Indexed keywords

GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PALLIATIVE THERAPY; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PALLIATIVE CARE; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 41749110912     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-007-2147-4     Document Type: Article

References (20)

1. Warshaw AL, Castillo CF. Pancreatic carcinoma. New Eng J Med 1992;326:455-465.
2. Niederhuber JE, Brennan MF, Menck HR. The national cancer data base report on pancreatic cancer. Cancer 1995;76:1671-1677.
3. Cameron JL, Crist DW, Sitzmann JV, Hruban RH, Boitnott JK, Seidler AJ, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991;161:120-125.
4. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Ann Surg 1996;223:273-279.
5. Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005;128:1642-1654.
6. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, et al. Pancreatic cancer registry in Japan: 20 years of experience. Pancreas 2004;28:219-230.
7. Pancreatic Section, British Society of Gastroenterology; Pancreatic Society of Great Britain and Ireland; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland; Royal College of Pathologists; Special Interest Group for Gastro-Intestinal Radiology. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 2005;54:1-16.
8. Fujino Y, Suzuki Y, Kamigaki T, Mitsutsuji M, Kuroda Y. Evaluation of gastroenteric bypass for unresectable pancreatic cancer. Hepatogastroenterology 2001;48:563-567.
9. Lillemoe KD, Cameron JL, Yeo CJ, Sohn TA, Nakeeb A, Sauter PK, et al. Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg 1996;223:718-728.
10. Kuhlmann K, de Gastro S, van Heek T, Busch O, van Gulik T, Obertop H, et al. Microscopically incomplete resection offers acceptable palliation in pancreatic cancer. Surgery 2006;139:188-196.
11. Rothenberg ML, Moore MJ, Cripps MC, Anderson JS, Portenoy RK, Burris HA 3rd, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-353.
12. Burris HA 3rd, Moore MJ, Anderson J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
13. Fujino Y, Ueda T, Kamigaki T, Takase S, Ajiki T, Kamoda Y, et al. Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer. Pancreas 2007;34:335-339.
14. Sobin LH, Wittekind, eds. UICC-TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss; 2002.
15. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
16. National Cancer Institute - Cancer Therapy Evaluation Program. Common toxicity criteria. Version 2.0. 30 April 1999.
17. Imamura M, Doi R. Treatment of locally advanced pancreatic cancer: should we resect when respectable? Pancreas 2004;28:293-296.
18. Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman J, et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 1999;230:322-330.
19. van Wagensveld BA, Coene PP, van Gulik TM, Rauws EA, Obertop H, Gouma DJ. Outcome of palliative biliary and gastric bypass surgery for pancreatic head carcinoma in 126 patients. Br J Surg 1997;84:1402-1406.
20. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-3743.